K. Morimoto

发表

Transplantation for Congenital Bone Marrow Failure Syndromes

K. Sakamoto, G. Schiller, T. Moore, 2010, Bone marrow research.

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

T. Kijima, K. Takayama, J. Uchino, 2022, Diagnostics.

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

K. Takayama, Tadaaki Yamada, Shinsaku Tokuda, 2022, JTO clinical and research reports.

Zebrafish Models for Dyskeratosis Congenita Reveal Critical Roles of p53 Activation Contributing to Hematopoietic Defects through RNA Processing

Bo Zhang, Shuo Lin, N. Danilova, 2012, PloS one.

Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study

K. Takayama, Tadaaki Yamada, H. Yoshioka, 2022, Frontiers in Oncology.

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2021, Journal of Cancer Research and Clinical Oncology.

A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.

O. Ukimura, K. Takayama, N. Katoh, 2022, International immunopharmacology.

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Journal of Cancer Research and Clinical Oncology.

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

M. Horinaka, T. Sakai, S. Yano, 2022, Cancer medicine.

Defects of protein production in erythroid cells revealed in a zebrafish Diamond–Blackfan anemia model for mutation in RPS19

Bo Zhang, S. Lin, S. Lin, 2014, Cell Death and Disease.

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

M. Horinaka, T. Sakai, Ryohei Katayama, 2022, npj Precision Oncology.

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

T. Mitsudomi, S. Yano, K. Takayama, 2022, Cancer science.

The functions of RPS19 and their relationship to Diamond-Blackfan anemia: a review.

K. Sakamoto, K. Morimoto, Shou Lin, 2007, Molecular genetics and metabolism.

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

Tadaaki Yamada, T. Kurata, H. Yoshioka, 2023, Cancers.

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer

Young Hak Kim, K. Takayama, K. Azuma, 2023, Cancer Immunology, Immunotherapy.

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

K. Takayama, K. Azuma, Tadaaki Yamada, 2022, JTO clinical and research reports.

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Young Hak Kim, M. Horinaka, T. Sakai, 2023, npj Precision Oncology.

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

Tadaaki Yamada, Y. Kaneko, Shinsaku Tokuda, 2023, Supportive Care in Cancer.

Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy

Tadaaki Yamada, Shinsaku Tokuda, T. Harada, 2023, Drugs & Aging.

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)

Tadaaki Yamada, Shinsaku Tokuda, K. Morimoto, 2023, Therapeutic advances in medical oncology.

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer

T. Kijima, Tadaaki Yamada, M. Tamiya, 2023, JAMA network open.

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

Tadaaki Yamada, K. Itoh, Shinsaku Tokuda, 2023, JTO clinical and research reports.

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer

Young Hak Kim, K. Takayama, Tadaaki Yamada, 2023, Cancer Medicine.

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report

Tadaaki Yamada, Shinsaku Tokuda, Seita Kataoka, 2023, Respirology case reports.

Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study

Tadaaki Yamada, Shinsaku Tokuda, Yasuhiro Goto, 2023, Targeted Oncology.

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.

Tadaaki Yamada, Shinsaku Tokuda, T. Harada, 2023, JTO Clinical and Research Reports.

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

Tadaaki Yamada, Y. Kaneko, Shinsaku Tokuda, 2023, Supportive Care in Cancer.

Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer

K. Takayama, Tadaaki Yamada, Shinsaku Tokuda, 2022, AntiCancer Research.

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

Tadaaki Yamada, M. Tamiya, Shinsaku Tokuda, 2023, Targeted Oncology.

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

M. Tamiya, Shinsaku Tokuda, Yasuhiro Goto, 2024, Frontiers in Immunology.

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

K. Kunimasa, Shinsaku Tokuda, K. Morimoto, 2024, Cancer letters.

Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study

M. Tamiya, Shinsaku Tokuda, Yasuhiro Goto, 2024, Frontiers in immunology.

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.

Shinsaku Tokuda, K. Morimoto, Yuki Katayama, 2024, Targeted oncology.